Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Study ID
NCT06758375
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Multiple Myeloma, Newly Diagnosed

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Low-dose teclistamab — DRUG
    NDMM patients will receive VRd 3x cicles followed by low dose teclistamab.

Study Details

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

Key Dates

Start date
Mar 3, 2025
Status verified
Mar 2025
Primary completion
Sep 7, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    Patients receiving 3 cycles of VRd followed by low-dose teclistamab.

Primary Outcome Measure

To determine general response [ Time Frame: 18 months after last teclistamab dose ]

Central Contacts

Related Studies